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Background – In recent years, use of transcatheter aortic valve replacement (TAVR) has expanded to include 
patients at intermediate- and low-risk cohorts. We sought to determine disease prevalence and treatment distribution 
including TAVR eligibility in low-risk patients across 37 advanced economies.     
 
Methods and Results – Four systematic searches were conducted across MEDLINE, EMBASE, and the Cochrane 
database for studies evaluating disease prevalence, severity, decision-making and survival in patients with AS. 
Estimates of disease prevalence and treatment eligibility were calculated using stochastic simulation and population 
data for the 37 countries comprising the IMF ‘advanced economies’ index. Fifty-six studies comprising 42,965 
patients were included across five domains: prevalence, severity, symptom status, treatment modality and outcome. 
The pooled prevalence in the general population aged 60-74 years and >75 years was 2.8% (95% CI: 1.4–4.1%) and 
13.1% (95% CI: 8.2–17.9%), respectively – corresponding to an estimated 16.1 million (95% CI: 12.2–20.3) people 
in 37 advanced economies. Of these, an estimated 3.2 million (95% CI: 2.2–4.4) patients have severe AS with 1.9 
million (95% CI: 1.3–2.6) eligible for surgical aortic valve replacement (SAVR). There are approximately 485,230 
(95% CI: 284,547–667,353) high-risk/inoperable patients, 152,690 (95% CI: 73,410–263,000) intermediate-risk 
patients and 378,890 (95% CI: 205,130–610,210) low-risk patients eligible for TAVR.  
 
Conclusions – With a prevalence of 4.5%, an estimated 16.1 million people aged ≥60 years across 37 advanced 
economies have AS. Of these, there are approximately 1.9 million patients eligible for SAVR and 1.0 million 
patients eligible for TAVR.  
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Introduction 
Since the release of the first PARTNER trial, transcatheter aortic valve replacement (TAVR) has been widely 
accepted as the preferred approach for selected high-risk/inoperable patients with severe symptomatic aortic 
stenosis (AS).1,2 In 2013, Osnabrugge and colleagues3 modelled the number of high-risk patients eligible for TAVR 
in the general population aged ≥75 years. The authors identified approximately 290,000 candidates across 21 
countries in Europe and North America. Since this report, the total number of TAVR procedures has grown to over 
200,000 across more than 1,000 centers in 50 countries.4 While surgical aortic valve replacement (SAVR) remains 
the primary modality for valve replacement in patients with severe AS,5 the use of TAVR in lower-risk patients is 
increasing as clinical practice anticipates the results of ongoing trials. Most recently, Edwards Lifesciences received 
expanded indication approvals from the US Food and Drug Administration for the SAPIEN 3 and SAPIEN XT in 
intermediate-risk patients. Unfortunately, there is limited data detailing the distribution of lower-risk patients 
eligible for TAVR (or SAVR). Indeed, quantification of disease prevalence and treatment eligibility will facilitate 
data-driven decision-making with respect to resource allocation, operator training and financial reimbursement.  
Accordingly, we sought to expand on previous modelling to determine disease prevalence, treatment 
distribution and survival outcomes for patients with severe AS aged ≥60 years. Using a mixed methodology of 
meta-analysis and stochastic simulation, our analysis estimates the number of patients with severe AS eligible for 
AVR across 37 countries comprising the International Monetary Fund’s (IMFs) 2015 ‘advanced economies’ index. 
 
Methods 
Four systematic searches were conducted across MEDLINE, EMBASE, and the Cochrane database for studies 
evaluating disease prevalence, severity, decision-making and outcomes in patients with AS. Search terms (and 
combinations thereof) included: ‘aortic stenosis’, ‘valvular heart disease’, ‘prevalence’, ‘epidemiology’, ‘severe’, 
‘symptomatic’, ‘surgical aortic valve’ or ‘SAVR’, and ‘transcatheter aortic valve’ or ‘TAVR’. Search results were 
limited to studies published in English during the 20-year period from January 1996 to December 2015. Citations 
were screened using the title and abstract, with the full article retrieved if it reported one or more of: disease 
prevalence in the general population, distribution of AS by severity with or without symptom status, SAVR and/or 
TAVR eligibility, risk profile in patients undergoing SAVR and postoperative mortality. Additional papers were 
identified from reference lists where appropriate. Studies were reviewed by two independent investigators at each 
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stage, with data extraction including study characteristics (i.e. author, year, journal, study design, enrollment period, 
inclusion criteria and AS definition), methodological quality and outcomes, as per the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement. Study quality was assessed using the Quality Index 
Assessment Criteria for Methodology of Studies, adopting a threshold of 12 for study inclusion.6 Disagreements 
relating to study inclusion were solved by consultation with a third investigator. Only original peer-reviewed 
publications enrolling patients from advanced economies were included in the analysis.  
Studies evaluating disease prevalence were included if they met the following criteria: (a) random sampling in 
a representative population, (b) diagnosis using objective echocardiographic assessment, and (c) outcomes reported 
by age category (or in a way that facilitates calculation of prevalence in the population aged ≥60 years). Studies 
directly or indirectly reporting disease severity were included if: (a) enrollment of patients was either random or 
consecutive and, (b) AS severity was determined by echocardiographic assessment. Studies directly or indirectly 
reporting AVR eligibility were included if: (a) enrolled patients had a priori defined severe AS, (b) symptom status 
was reported (with symptomatic AS defined by a clinical history of angina, syncope and/or congestive heart failure), 
and (c) intervention rate was reported for AVR as number of patients. Data pertaining to all-cause mortality were 
extracted from studies comparing outcomes in patients receiving SAVR or medical therapy. Studies reporting the 
risk profile of patients undergoing isolated SAVR were included if: (a) enrollment of patients was consecutive, (b) 
risk score was prospectively collected, and (c) patient risk was reported by category using a defined EuroSCORE 
threshold (or interval) or Society of Thoracic Surgery Predicted Risk Of Mortality (STS-PROM) score. Studies 
reporting TAVR eligibility were included if: (a) patients were referred for assessment of eligibility, (b) enrollment 
of patients was consecutive, and (c) enrollment was consistent with regional guidelines at the time of recruitment. 
The exclusion criteria reported in each individual study was not used to determine inclusion in the meta-analysis.   
Studies were excluded if one or more of the following criteria applied: duplicate publication, subgroup analysis 
of a previously reported cohort, publication in the form of an abstract, case report, conference presentation or 
editorial, undefined recruitment protocol and/or unclear reporting of outcomes such that the relevant statistics could 
not be extracted or calculated. Where duplicated data was identified, the study with the largest sample was used. 
With respect to TAVR eligibility, studies performed in the United States prior to the release of PARTNER I 
(NCT00530894) findings were excluded due to stricter inclusion criteria which have since eased in line with earlier 
European trials. 
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Disease prevalence, represented as rate and 95% confidence interval (95% CI), was determined for each study 
population by extraction of sample size and patient number by age category. Thereafter, prevalence was evaluated 
as a pooled estimate using fixed and random-effects models, where appropriate. Patient progression to AVR was 
mapped using pooled estimates of: symptom status in patients with severe AS, risk score (EuroSCORE and/or STS-
PROM) and as-treated intervention rates. Individual patient characteristics were not obtained. Estimates of disease 
prevalence and treatment eligibility were calculated using Monte Carlo methods (n=100,000) with probability 
distributions parametrized using the aforementioned pooled statistics. Population estimates for 2015, 2016 and 2020 
were sourced for the 37 countries comprising the 2015 IMF ‘advanced economies’ index, namely: Australia, 
Austria, Belgium, Canada, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hong 
Kong, Iceland, Ireland, Israel, Italy, Japan, Latvia, Lithuania, Luxembourg, Malta, Netherlands, New Zealand, 
Norway, Portugal, San Marino, Singapore, Slovakia, Slovenia, South Korea, Spain, Sweden, Switzerland, Taiwan, 
United Kingdom, United States.7-8 The number of patients eligible for TAVR was estimated for high-, intermediate- 
and low-risk using EuroSCORE and adopting the inclusion age of PARTNER II (NCT01314313) for high-to-
intermediate risk and PARTNER III (NCT02675114) for low-risk patients. A separate analysis was performed using 
STS-PROM. The exclusion criteria for PARTNER was not modelled in the simulation. 
Data analysis was conducted using R Studio (GNU General Public License). Weighted point estimate (PE) and 
risk ratio (RR) were calculated for the pooled study population, with results presented as weighted PE or RR and 
95% CI. Fixed and random effects models utilized the inverse variance and DerSimonian-Laird methods, 
respectively. Statistical heterogeneity, a measure of variability across trials not due to chance, was assessed using 
the Cochran-Q and I2 statistics. Moderate heterogeneity was considered to be present for an I2>50% and p<0.10. 
Accordingly, conclusions were based on analysis using the random effects models. Sensitivity analysis was 
performed using the one-study exclusion method. A ≥15% modification of the pooled estimate was considered 
significant. Publication bias was assessed by inspection of funnel plots for asymmetry and Egger’s regression test 
with p<0.10 considered significant.  
 
Results 
Of the 4,514 studies identified during the systematic search, with an additional 47 found through cross-
referencing, 4,037 were excluded on initial review owing to inadequate diagnostic criteria, biased patient selection, 
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duplicate data, non-original publication and/or an unclear methodology (Figure 1). Following assessment of 524 
full articles, 56 studies were included for analysis with 42,965 patients extracted (not including 141,905 patients 
used for sensitivity analysis of preoperative risk score).  
Characteristics of the studies used to estimate disease prevalence are presented in Table 1 (see supplementary 
material for prevalence studies that were excluded due to patient selection and/or disease classification). Disease 
prevalence ranged from 1.3% to 7.8% for people aged 60-74 years and 2.6% to 22.8% for people aged ≥75 years. 
The pooled prevalence was 2.8% (95% CI: 1.4–4.1%) and 13.1% (95% CI: 8.2–17.9%), respectively (Figure 2a). 
The portion of AS classified as severe was reported in six of the nine populations ranging from 11.5% to 26.7%. 
The pooled estimate was 19.9% (95% CI: 12.8–26.9%; Figure 2b). 
Disease progression to SAVR and TAVR (for high-risk/inoperable patients) is reported in Figure 3 (see 
supplementary material for studies used to derive SAVR eligibility). Of those patients with severe AS, 71.2% (95% 
CI: 63.3–79.2%) were symptomatic (Figure 4), with SAVR performed in 56.1% (95% CI: 48.4–63.9%) of 
symptomatic patients and 28.8% (95% CI: 20.8– 46.7%) of asymptomatic patients (Figure 5). A further 39.9% 
(95% CI: 32.4–47.4%) of non-operated asymptomatic patients progressed to SAVR within 2 years due to 
development of symptoms necessitating surgical intervention. Of the patients who did not receive SAVR, 20.0% 
(95% CI: 12.3–27.7%) were deemed eligible but refused. Irrespective of symptom status, SAVR was associated 
with a significant reduction in mortality (up-to 2 years postoperatively) when compared to optimal medical therapy 
(RR: 0.34 [95% CI: 0.24–0.48] and RR: 0.37 [95% CI: 0.18–0.78]; Figure 6). Of the patients who underwent 
SAVR, 57.4% (95% CI: 41.3–73.6%) were classified as low-risk based on EuroSCORE assessment (Figure 7). The 
characteristics of studies investigating TAVR eligibility are presented in Table 2. Of the high-risk/inoperable 
patients referred for TAVR assessment, 56.0% (95% CI: 50.2–61.8%) were eligible (Figure 8), of which 84.6% 
(95% CI: 79.0–90.2%) received TAVR with 15.4% (95% CI: 9.8–21.0%) refusing intervention. 
The overall prevalence of AS in the study population was 4.5%, corresponding to an estimated 16.1 million 
(95% CI: 12.2–20.3) people across the 37 advanced economies. Disease prevalence and AVR eligibility for 2015, 
stratified by country and procedural type, are presented in Tables 3 and 4. By region, there is an estimated 7.5 
million (95% CI: 5.7–9.5) people in Europe, 4.5 million (95% CI: 3.5–5.7) people in North America and 350,190 
(95% CI: 266,950–440,760) people in Australasia with AS. Of these, an estimated 3.2 million (95% CI: 2.2–4.4) 
people aged ≥60 years have severe AS. An estimated 1.9 million (95% CI: 1.3–2.6) patients with severe AS are 
 - 7 - 
 
eligible to receive SAVR including 873,690 (95% CI: 596,290–1,208,500) in Europe, 515,690 (95% CI: 355,210–
706,910) in North America and 40,950 (95% CI: 28,220–56,170) in Australasia. Applying age and risk profiles 
from the PARTNER trial series, 485,230 (95% CI: 284,547–667,353) patients at high-risk and aged ≥75 are eligible 
for TAVR including 231,490 (95% CI: 136,880–351,490) in Europe, 125,060 (95% CI: 73,710–190,060) in North 
America and 10,130 (95% CI: 6,010–15,420) in Australasia. An additional 152,690 (95% CI: 73,410–263,000) 
patients aged ≥75 years and at intermediate-risk are now eligible for TAVR with the recent shift in approved 
indications. Extending further to low-risk patients, adopting an inclusion age of ≥65 years as per PARTNER III, 
another 378,890 (95% CI: 205,130–610,210) patients would be candidates for TAVR. Analysis using population 
projections for the next 5 years8 returns estimates of 331,359 (95% CI: 266,263–390,776) new cases of AS in 2016, 
with overall prevalence reaching 17.9 million patients (95% CI: 13.6–22.6) by 2020. Accordingly, there will be an 
estimated 2.1 million (95% CI: 1.4–2.9) patients eligible for SAVR and 1.1 million (95% CI: 0.6–1.7) patients 
eligible for TAVR by the end of this decade. 
Pooled estimates remained stable on sensitivity analysis for all parameters except prevalence in the general 
population aged 60-74. On removal of the Taiwanese-based study by Lin and colleagues11, adjusting prevalence to 
1.4% (95% CI: 1.2–1.6%), 300,000 fewer patients with severe AS were eligible for SAVR. Despite this, the 
estimated number of TAVR candidates remained similar at 485,247 (95% CI: 286,170–740,191). In a second 
analysis, the proportion of SAVR patients classified as high-, intermediate- and low-risk was adjusted to 6.2%, 
13.9% and 79.9%, respectively – based on a 2015 registry study that used STS-PROM score to classify 141,905 
patients who underwent isolated primary SAVR in the US from 2002 to 2010.51 Accordingly, the estimated number 
of patients eligible for TAVR in the high- and intermediate- risk groups was reduced by 39,185 (95% CI: 26,358–
53,887) and 79,254 (95% CI: 40,043–132,524), respectively. The difference was shifted to the low-risk group, 
totaling 527,256 (95% CI: 304,308–814,868). No evidence of publication bias was identified on Egger's test for 
measures of prevalence, symptom status or AVR eligibility. 
 
Discussion 
This meta-analysis presents a quantitative analysis of the progression of severe AS, from diagnosis to 
intervention, extending the current understanding of patient distribution along the path to AVR. Moreover, this 
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study quantifies the breadth of disease burden in advanced economies highlighting the need for expansion in 
operational capacity and payer reimbursement.  
The present study reports a disease prevalence of 2.8% and 13.1% in the general population aged 60-74 years 
and ≥75 years, respectively. Subsequent modelling estimates that 16.1 million people across 37 advanced 
economies have AS. Of these, 1.9 million patients are eligible for SAVR with 485,230 high-risk/inoperable patients 
eligible for TAVR. These figures underscore the growing disparity between the number of replacement procedures 
and clinical need for treatment. SAVR is projected to reach 500,000 cases per year by 2020.52 Even if patient 
demand remained stable, this number is inadequate. Our analysis projects 17.9 million patients will have AS within 
5 years, or approximately 331,300 new cases per year including 65,600 patients diagnosed with severe AS.  
The data used to quantify each step of the analysis (from prevalence to TAVR eligibility) were extracted from 
studies performed in advanced economies. Accordingly, estimates of disease prevalence and patient eligibility were 
restricted to the 37 countries comprising the IMF advanced economies index. Inherent in the study design is the 
assumption that prevalence and intervention rates are generalizable across these countries. In reality, there are likely 
to be differences from one country to the next. Indeed, favorable reimbursement schemes and local decision-making 
may result in differing eligibility rates across countries. Moreover, the IMF advanced economies index represents 
less than 15% of the world’s population.8  
Distribution of patients along the AVR pathway raises a number of questions. The literature has consistently 
demonstrated mortality rates of up to 50% within 3-5 years from symptom onset in patients with severe AS.53-55 Yet, 
this study reports that more than 40% of patients with severe symptomatic AS did not undergo SAVR. Equally 
surprising, less than 30% of patients with asymptomatic AS underwent SAVR despite at least a 25% reduction in 
mortality when compared to medical therapy. It should be noted that five of the six studies reporting outcomes for 
asymptomatic AS included patients with low LVEF. This cohort of asymptomatic patients is known to have poorer 
outcomes. Accordingly, their inclusion may have disproportionately influenced the observed mortality benefit with 
SAVR. Likewise, it may also have contributed to the finding that close to half of the asymptomatic patients treated 
with medical therapy progressed to SAVR within 2 years following symptom onset. Irrespective of symptom status, 
20% of patients who received medical therapy did so because they refused surgical intervention. The reasons for 
treatment refusal were not explored in this study and may include reimbursement. Nevertheless, these data 
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underscore the disparity between the number of patients estimated as having AS and the number of patients 
undergoing SAVR over the past two decades. 
With respect to TAVR, notwithstanding the rapid rise in adoption since the first procedure in 2002,56 the 
present meta-analysis indicates that only 56% of high-risk/inoperable patients referred for TAVR were eligible. This 
is not entirely unexpected given that TAVR was initially reserved for contraindicated surgical patients. Using data 
from the German Aortic Valve Registry, Reinöhl and colleagues have shown an overall increase in the number of 
AVR procedures between 2007-2013 with TAVR increasing by 9,003 compared to a decrease in SAVR by 1,574.57 
The majority of this increase was seen in the cohort aged 80 years or more whereby a small reduction in SAVR was 
considerably outpaced by the increase in TAVR. This suggests that the two modalities are complementary with 
additional patients being treated beyond those who would have previously undergone SAVR. In contrast, TAVR in 
younger patients offset the reduction in SAVR suggesting that TAVR in the ‘lower-risk’ population will compete 
with SAVR. Of note, Germany has one of highest rates of TAVR adoption in Europe as a result of their TAVR-
specific national diagnosis-related group reimbursement scheme. In 2013, Mylotte and colleagues58 demonstrated a 
3.3-fold increase in the number of TAVR procedures per million population in healthcare systems using TAVR-
specific reimbursement schemes. In countries with lower rates of TAVR adoption, it is possible that TAVR has 
been limited to inoperable patients. Thus, a shift towards lower-risk patients will see TAVR compete directly with 
SAVR, with an estimated 530,000 patients being eligible for both TAVR and SAVR.  
A significant barrier to TAVR adoption is the costs associated with device procurement and implantation. 
Moreover, the cost-effectiveness compared to SAVR is unclear. Analysis of the US CoreValve High-Risk Trial has 
demonstrated higher index admission and projected lifetime costs with TAVR when compared to SAVR ($11,260 
and $17,849 increase per patient, respectively).59 In contrast, transfemoral access was associated with lower costs 
and higher QALYs gained in PARTNER I – with TAVR being dominant over SAVR in 70.9% of bootstrap 
replicates (ICER<$50,000/QALY).60  
Irrespective of treatment modality, the estimated number of patients in need of valve replacement presents a 
considerable challenge to policy makers. From a fiscal perspective, treating all patients eligible for valve 
replacement in this study would require a budget of at least $149.9 billion (95% CI lower bound) - calculated using 
mean 12-month cost from PARTNER I.38 Aside from the direct financial costs of the procedure, additional 
treatment centers and operators would be required. Expansion of TAVR to low-risk patients may prompt a reduction 
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in device cost allowing for earlier intervention thus redirecting financial resources to training or infrastructure. 
Reductions in procedural time, hospital length of stay and rehabilitation days,
38
 may allow for a higher throughput 
of patients – ultimately increasing the number of beds and staff available. However, it should be noted that the long-
term durability of TAVR remains unknown following recent reports indicating deterioration within 10 years for the 
first generation of transcatheter valves.61 Likewise, it remains unclear as to whether TAVR is, at the least, non-
inferior to SAVR in the low-risk cohort. The purpose of the present study was to quantify current treatment patterns 
and estimate patient eligibility. Any decision to expand TAVR into younger, low-risk patients will require evidence 
of durability and outcomes comparable to SAVR. In the short-term, SAVR will likely remain the primary modality 
for valve replacement in this cohort – especially for younger patients and/or patients with asymptomatic disease. 
 
Study Limitations 
With respect to estimating patient numbers, measures of uncertainty were incorporated at each step to calculate 
intervals representing the likelihood of the final estimates. For TAVR eligibility, estimates may disproportionately 
represent European experience as risk profile was determined using EuroSCORE. The decision to use EuroSCORE 
for the primary analysis was based on the greater number of included studies reporting EuroSCORE relative to STS-
PROM. The decision to include studies that used hospital-based eligibility criteria and not a specific trial standard 
(i.e. the PARTNER exclusion criteria) was based on the desire to provide findings that represent broader clinical 
practice. 
For estimates of postoperative survival, the concomitant effect of coexisting disease could not be directly 
assessed. While risk profile measures like EuroSCORE or STS-PROM score may be used as a surrogate for AVR 
patients, these scores do not capture every characteristic that may affect outcomes. Unfortunately, individual patient 
data was not provided to enable matching or reporting of sex-based and racial/ethnic-based differences. 
Additionally, patients receiving medical therapy were not stratified by risk. Accordingly, patients who refused 
SAVR were included in estimates of SAVR eligibility but not TAVR eligibility.  
Although studies in this analysis used echocardiography to identify AS classification criteria varied. The 
influence of differing methodologies on estimates of disease prevalence, severity and symptom status should be 
considered when interpreting the results of this study. Heterogeneity was explored by comparison of study 
characteristics, assessment of funnel plot asymmetry and Egger's linear regression method, where appropriate. The 
 - 11 - 
 
repeatedly high I2 statistic increases the uncertainty of the patient estimates with each successive step in the 
simulation. Sensitivity analysis was employed in the case of prevalence in the general population aged 60-74 years. 
Likewise, a separate analysis was performed substituting EuroSCORE for STS-PROM. The reduction in estimated 
SAVR candidates with a change in the initial prevalence parameter highlights the limitations of the modelling 
approach, specifically the dependence on the methodologies of the studies comprising the meta-analysis.  
In conclusion, the present study adopted a mixed methodology of meta-analysis and stochastic simulation to 
quantify the growing burden of AS, specifically the progression of severe AS to AVR. Based on AHA/ACC 
guidelines, 4.5% of people aged ≥60 years have AS or 16.1 million people across 37 advanced economies. Of these, 
approximately 1.9 million patients with severe AS are candidates for SAVR. For high-to-intermediate risk patients 
aged ≥75 years, approximately 637,000 patients are eligible for TAVR. A further 379,000 patients would be eligible 
following expanded indication approval to include the low-risk cohort. Given the trend towards TAVR in lower-risk 
patients, together with an ageing population, healthcare systems must look at ways to accommodate the increase in 
patient numbers, operator shortage and hospitalization of untreated patients with severe AS. 
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Table 1  Characteristics of studies included to determine prevalence of severe AS 
Author., 
Year 














9Iivanainen et al., 
1996 








- 77% inclusion rate 
Yes Aged ≥75yrs 
Female: 73% 
Mild AS: Vratio ≤0.55, AVA: ≤1.5cm
2  
Moderate AS: Vratio ≤0.45, AVA: 
≤1.2cm2  
Severe AS: Vratio ≤0.35, AVA: ≤0.8cm
2 
10Stewart et al.,  
1997  











- 57% inclusion rate 
n/a Aged ≥65yrs 
Female: 57% 
AS: Vmax >2.5m/s 




Taipei, Taiwan 2004 Referral  Routine health 
review and/or non-
cardiac surgery 
Yes Aged 20-97yrs 
Female: 41% 
Mild-moderate AS: gradient 
>20mmHg 
Severe AS: gradient ≥50mmHg 
12Nkomo et al.,  
2006* 









- 90% inclusion rate 
Yes Aged ≥18yrs 
Female: 51% 
Mild AS: Vmax 2.5-3m/s, AVA: 
>1.5cm2  
Moderate AS: Vmax 3-4m/s, AVA: 1-
1.5cm2 
Severe AS: Vmax ≥4m/s, AVA 
<1.0cm2 







Invitation (at 90yrs) Leiden 85-plus 
Study (n=277) 
 
Yes Aged 90yrs 
Female: 67% 
Mild AS: gradient <25mmHg 
Moderate AS: gradient 25-40mmHg 
Severe AS: gradient >40mmHg 
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14Eveborn et al., 
2012* 
3,273 Tromsø, Norway 
 







n/a Aged 25-84yrs 
Female: 49% 
Mild AS: gradient 15–29mmHg 
Moderate AS: gradient 30–49mmHg 
Severe AS: gradient ≥50mmHg 
15Malouf et al.,  
2012≠ 








Yes Age: 74 ± 
14yrs 
Female: 56% 
Mild AS: AVA: >1.5cm2  
Moderate AS: AVA: 1.0-1.5cm2  
Severe AS: AVA: <1.0cm2 
16Leibowitz et al.,  
2013 
498 Jerusalem, Israel 2005-
2006 
Random selection Jerusalem 
Longitudinal Cohort 
Study (n=1,222) 
n/a Aged ≥85yrs 
Female: 53% 
AS: Vmax >2.5m/s 
17Rezzoug et al.,  
2015 









review (29 GP 
clinics) 
Yes Aged ≥80yrs 
Female: 63% 
Mild AS: AVA: >1.5cm2  
Moderate AS: AVA: 1.0-1.5cm2  
Severe AS: AVA: <1.0cm2 
AS = Aortic Stenosis, AVA = aortic valve area, Vmax = peak velocity, Vratio = velocity ratio;  
*portion of the study population extracted (patients aged ≥60 yrs); #number of patients included in meta-analysis (not total study sample); ≠included for severity classification 
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Table 2  Characteristics of studies included to determine TAVR eligibility 
Author 
Year 












40Otten et al.,  
2008 
 
100 Rotterdam, Netherlands 
 
2005-2007 Severe symptomatic AS 
Aged ≥75yrs or EuroSCORE >20 
Yes Age: 82 ± 8yrs 
Female: 57% 
EuroSCORE: 17 ± 11 
CoreValve 
41Himbert et al.,  
2009 
160 Paris, France 
 
2006-2008 Severe symptomatic AS  
High-risk/inoperable  
EuroSCORE >20 (STS-PROM ≥10) 
Life expectancy >1yr 
Yes Not-reported SAPIEN 
42De Carlo et al.,  
2010 
166 Pisa, Italy 
 
2007-2009 Severe symptomatic AS  
High-risk/inoperable  




43Ragani et al.,  
2010 
 
85 Brighton, UK 
 
2007-2009 Severe AS 
Inoperable  
 




44Saia et al.,  
2010 
98 Bologna, Italy 
 
2007-2008 Severe symptomatic AS  
Inoperable 
Yes Age: 82 ± 7yrs 
Female: 60% 
EuroSCORE: 25.3 ± 14.5 
SAPIEN and 
CoreValve 
45Bainey et al.,  
2013 
 
170 Ontario, Canada  
 
2008-2011 Severe symptomatic AS  
High-risk/inoperable  
Yes Age: 82.1 ± 6.5yrs 
Female: 53% 
STS-PROM: 10.5 ± 7.6 
SAPIEN 
46Dubois et al.,  
2013 
 
163 Leuven, Belgium 
 
2008-2011 Severe symptomatic AS  
High-risk/inoperable  
Advanced age + one coexisting 
illness 
Yes Age: 83 ± 5yrs 
Female: 56% 
SAPIEN 
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47Hong et al.,  
2014 
 
60 Seoul, Korea 
 
2011-2012 Severe symptomatic AS  
High-risk/inoperable  
EuroSCORE >20 (STS-PROM ≥10) 
Yes Age: 80 ± 5yrs 
Female: 58% 
EuroSCORE: 18.4 ± 14.3 
CoreValve 
48O'Sullivan et al.,  
2014 
105 Dublin, Ireland 
 
2009-2012 Severe AS  
High-risk/inoperable  
Yes Age: 83.2 ± 20.8yrs 
Female: 38% 
Not-specified 
49Iglesias et al.,  
2015 
 
149 Madrid, Spain 
 
2008-2012 Severe symptomatic AS  
Indication for AVR 
Yes Age: 83.7 ± 5.9yrs 
Female: 57% 
EuroSCORE: 19.8 ± 12.3 
SAPIEN 
50Pilgrim et al.,  
2015 
442 Bern, Switzerland 
 
2007-2010 Severe symptomatic AS  
High-risk/inoperable 





AS = Aortic Stenosis, AVR = Aortic Valve Replacement, STS-PROM = Society of Thoracic Surgery Predicted Risk Of Mortality; Continuous variables expressed as mean ± SD or median; categorical 
variables expressed as percentage 
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Table 3  Prevalence of AS in the general population aged ≥60yrs  
Country Aortic Stenosis  Severe AS Eligible for SAVR 
 Australia 295,712 (226,107-372,421) 58,849 (40,826- 80,437) 34,578 (23,799-47,538) 
 Austria 134,901 (102,575-170,563) 26,846 (18,459-36,857) 15,775 (10,766-21,805) 
 Belgium 180,667 (137,212-228,532) 35,955 (24,656-49,446) 21,126 (14,409-29,251) 
 Canada 480,853 (367,347-604,926) 95,691 (66,265-130,373) 56,225 (38,684-77,093) 
 Cyprus 12,163 (9,307-15,298) 2,420 (1,690-3,292) 1,422 (985-1,943) 
 Czech Republic 149,495 (114,316-187,965) 29,747 (20,719-40,370) 17,480 (12,076-23,915) 
 Denmark 82,816 (63,254-104,197) 16,479 (11,450-22,438) 9,683 (6,673-13,247) 
 Estonia 21,862 (16,602-27,651) 4,350 (2,992-5,971) 2,556 (1,744-3,533) 
 Finland 90,954 (69,370-114,679) 18,100 (12,523-24,720) 10,635 (7,312-14,623) 
 France 1,117,420 (848,647-1,414,286) 222,413 (152,287-306,733) 130,686 (88,684-181,424) 
 Germany 1,529,513 (1,157,064-1,939,629) 304,438 (208,059-420,453) 178,877 (121,139-249,001) 
 Greece 205,612 (155,563-261,091) 40,917 (27,905-56,548) 24,041 (16,256-33,441) 
 Hong Kong 97,987 (74,708-123,670) 19,501 (13,506-26,685) 11,459 (7,863-15,777) 
 Iceland 3,824 (2,922-4,822) 761 (527-1,039) 447 (307-615) 
 Ireland 49,222 (37,671-61,922) 9,795 (6,830-13,289) 5,756 (3,982-7,859) 
 Israel 79,789 (60,862-100,522) 15,877 (10,989-21,667) 9,330 (6,419-12,832) 
 Italy 1,202,143 (910,283-1,523,895) 239,248 (163,346-330,570) 140,579 (95,229-195,484) 
 Japan 2,838,264 (2,152,427-3,594,256) 564,840 (386,311-778,508) 331,893 (225,343-460,078) 
 Latvia 33,382 (25,343-42,210) 6,642 (4,569-9,118) 3,903 (2,662-5,389) 
 Lithuania 49,018 (37,163-62,070) 9,754 (6,679-13,418) 5,731 (3,896-7,940) 
 Luxembourg 6,835 (5,206-8,631) 1,360 (941-1,861) 799 (548-1,100) 
 Malta 6,376 (4,874-8,023) 1,269 (882-1,725) 745 (514-1,019) 
 Netherlands 249,164 (190,297-313,669) 49,577 (34,401-67,501) 29,130 (20,070-39,905) 
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 New Zealand 54,478 (41,630-68,556) 10,841 (7,525-14,757) 6,370 (4,396-8,733) 
 Norway 68,233 (52,101-85,951) 13,578 (9,419-18,529) 7,978 (5,492-10,951) 
 Portugal 186,634 (141,740-236,160) 37,139 (25,420-51,025) 21,824 (14,838-30,191) 
 San Marino 529 (401-670) 105 (72-145) 62 (42-86) 
 Singapore 53,114 (40,675-66,774) 10,569 (7,395-14,307) 6,210 (4,315-8,457) 
 Slovakia 61,858 (47,332-77,757) 12,309 (8,592-16,690) 7,233 (5,011-9,864) 
 Slovenia 32,688 (24,941-41,241) 6,505 (4,488-8,892) 3,822 (2,620-5,263) 
 South Korea 551,545 (421,061-694,339) 109,768 (76,096-149,490) 64,498 (44,369-88,319) 
 Spain 766,704 (580,322-972,528) 152,576 (104,508-210,222) 89,648 (60,924-124,428) 
 Sweden 155,088 (118,237-195,792) 30,862 (21,359-42,155) 18,135 (12,446-24,948) 
  Switzerland 125,436 (95,435-158,507) 24,969 (17,172-34,227) 14,671 (10,009-20,244) 
 Taiwan 248,178 (189,762-312,434) 49,387 (34,299-67,160) 29,022 (19,958-39,766) 
 United Kingdom 949,884 (723,886-1,197,791) 189,044 (130,372-258,725) 111,085 (75,996-153,019) 
 United States 3,928,656 (3,001,571-4,942,710) 781,773 (542,923-1063,142) 459,344 (316,429-628,430) 
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Table 4  Number of patients with severe symptomatic AS eligible for TAVR 
Country High-risk/inoperable (≥75yrs)   Intermediate-risk (≥75yrs)   Low-risk (≥65yrs)   
 Australia 8,595 (5,087-13,081) 2,705 (1,299-4,659)  6,870 (3,732-11,040) 
 Austria 4,137 (2,443-6,295) 1,302 (627-2,244) 3,222 (1,748-5,193) 
 Belgium 5,610 (3,320-8,526) 1,765 (850-3,028) 4,280 (2,328-6,870) 
 Canada 13,795 (8,164-20,947) 4,340 (2,082-7,458) 11,063 (5,999-17,804) 
 Cyprus 338 (200-513) 106 (51-182) 277 (150-446) 
 Czech Republic 4,080 (2,416-6,195) 1,284 (617-2,206) 3,414 (1,845-5,486) 
 Denmark 2,348 (1,389-3,570) 738 (355-1,267) 1,947 (1,055-3,135) 
 Estonia 676 (401-1,027) 213 (102-366) 515 (280-826) 
 Finland 2,646 (1,566-4,009) 833 (401-1,432) 2,131 (1,156-3,430) 
 France 34,837 (20,494-53,058) 10,959 (5,251-18,842) 26,521 (14,385-42,635) 
 Germany 48,621 (28,745-73,889) 15,298 (7,336-26,307) 36,606 (19,867-58,771) 
 Greece 6,646 (3,929-10,114) 2,090 (1,009-3,585) 4,979 (2,717-7,999) 
 Hong Kong 2,885 (1,704-4,389) 908 (436-1,556) 2,231 (1,207-3,586) 
 Iceland 111 (65-168) 35 (17-60) 88 (48-141) 
 Ireland 1,362 (803-2,068) 429 (206-738) 1,120 (606-1,801) 
 Israel 2,298 (1,360-3,498) 723 (348-1,246) 1,823 (989-2,932) 
 Italy 38,459 (22,697-58,469) 12,105 (5,809-20,841) 28,975 (15,723-46,582) 
 Japan 89,452 (52,843-135,992) 28,142 (13,539-48,333) 68,655 (37,183-110,057) 
 Latvia 1,030 (609-1,567) 324 (155-555) 790 (429-1,266) 
 Lithuania 1,539 (912-2,338) 484 (234-827) 1,163 (632-1,865) 
 Luxembourg 205 (121-312) 64 (31-111) 159 (87-256) 
 Malta 177 (105-269) 56 (27-96) 148 (80-239) 
 Netherlands 7,154 (4,232-10,887) 2,252 (1,082-3,868) 5,798 (3,139-9,338) 




 New Zealand 1,539 (910-2,335) 484 (233-833) 1,255 (680-2,021) 
 Norway 1,966 (1,167-2,997) 619 (297-1,064) 1,594 (863-2,566) 
 Portugal 5,815 (3,437-8,826) 1,829 (884-3,142) 4,449 (2,425-7,118) 
 San Marino 17 (10-25) 5 (3-9) 13 (7-20) 
 Singapore 1,362 (804-2,071) 428 (207-736) 1,149 (623-1,851) 
 Slovakia 1,650 (976-2,505) 519 (250-892) 1,366 (739-2,200) 
 Slovenia 975 (576-1,480) 307 (147-527) 753 (408-1,210) 
 South Korea 15,522 (9,164-23,590) 4,884 (2,352-8,420) 12,545 (6,768-20,205) 
 Spain 24,165 (14,319-36,701) 7,603 (3,655-13,076) 18,334 (9,972-29,419) 
 Sweden 4,586 (2,706-6,983) 1,443 (693-2,475) 3,694 (1,995-5,935) 
  Switzerland 3,812 (2,245-5,811) 1,199 (576-2,065) 2,977 (1,614-4,791) 
 Taiwan 7,023 (4,159-10,670) 2,209 (1,059-3,791) 5,524 (2,999-8,898) 
 United Kingdom 28,577 (16,905-43,477) 8,993 (4,317-15,475) 22,576 (12,227-36,245) 
 United States 111,205 (65,763-168,903) 34,991 (16,813-60,098) 89,736 (48,766-143,992) 
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Figure 1  Search methodology 
 
Figure 2  Forest plots showing prevalence of severe AS; (upper) AS in general population aged ≥60 years; random 
effects models (n=26,320); (lower) proportion of AS classified as severe; random effects models (n=1,484) 
 
Figure 3  Map of disease progression to SAVR (includes TAVR pathway for high-risk/inoperable patients); as-
treated analysis (n=42,965) 
 
Figure 4  Forest plot showing the proportion of severe AS patients reported as symptomatic; random effects models 
(n=9,658) 
 
Figure 5  Forest plot showing the proportion of patients with severe AS who underwent SAVR; random effects 
models (n=8,034) 
 
Figure 6  Forest plot showing all-cause mortality in patients treated for severe AS (AVR vs. medical therapy); 
random effects models (n=3,061) 
 
Figure 7  Forest plot showing the risk profile (EuroSCORE) of patients treated with SAVR; random effects models 
(n=2,770) 
 
Figure 8  Forest plot showing the eligibility of high-risk/inoperable patients referred for TAVR; random effects 
models (n=1,698) 
 
